Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
FTL 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FTL 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for FTL, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FTH1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FTH1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for FTH1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FSP1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FSP1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for FSP1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FOLR2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FOLR2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for FOLR2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
FOLR1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
FOLR1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for FOLR1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
EZH2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
EZH2 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for EZH2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
EZH1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
EZH1 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for EZH1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
EP300 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
EP300 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for EP300, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
EED 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
EED 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for EED, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
DUB3 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
DUB3 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for DUB3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
DPYD 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
DPYD 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for DPYD, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →
DNMT3B 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
8 min read
DNMT3B 2026 Target Evaluation Report Update: Biology, Validation, Competition, IP, and R&D Strategy
15 July 2026
A visual target evaluation report for DNMT3B, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Read →